Lareq Pharma

Lareq Pharma is a Swedish biotechnology company based in Lund that specializes in the development of novel small molecule therapies for chronic respiratory diseases. The company's primary focus is on Chronic Obstructive Pulmonary Disease (COPD), aiming to provide more effective anti-inflammatory treatments through inhaled delivery. Its lead program, LRQ-15, is a selective inhibitor designed to reduce lung inflammation while minimizing the systemic side effects typically associated with oral medications. Founded by a team of experienced researchers from the pharmaceutical industry, Lareq Pharma operates within the Medicon Village life science cluster. The company leverages its deep expertise in medicinal chemistry and respiratory biology to advance its pipeline toward clinical validation.